Home » Stocks » ALX Oncology Holdings

ALX Oncology Holdings, Inc. (ALXO)

Stock Price: $44.19 USD 0.23 (0.52%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.61B
Revenue (ttm) 4.42M
Net Income (ttm) n/a
Shares Out 36.49M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $44.19
Previous Close $43.96
Change ($) 0.23
Change (%) 0.52%
Day's Open 43.90
Day's Range 41.50 - 44.50
Day's Volume 67,977
52-Week Range 28.01 - 50.00

More Stats

Market Cap 1.61B
Enterprise Value 1.51B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.49M
Float 1.23M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 364.87
PB Ratio n/a
Revenue 4.42M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 99.51M
Net Cash / Share 2.73
Gross Margin 9.87%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-4.36-1.88
Operating Income-23.98-15.75
Net Income-19.24-13.73
Shares Outstanding20.2518.10
Earnings Per Share-1.15-0.96
Operating Cash Flow-14.25-13.19
Capital Expenditures-0.35-0.65
Free Cash Flow-14.60-13.84
Cash & Equivalents9.028.26
Total Debt5.42-
Net Cash / Debt3.608.26
Book Value-70.64-51.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ALX Oncology Holdings, Inc.
Country United States
Employees 24
CEO Jaume Pons

Stock Information

Ticker Symbol ALXO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALXO
IPO Date July 17, 2020


ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.